Pfizer's ketohexokinase inhibitor decreases liver fat content in NAFLD Phase II

As Pfizer considers which combination therapies to develop for NASH, the pharma reported that its KHK inhibitor, PF-06835919, as monotherapy reduced whole liver fat in a Phase II trial to treat non-alcoholic

Read the full 326 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE